BioNTech SE reported second-quarter 2025 revenue of €260.8 million, more than 70 % above analyst expectations, as higher COVID-19 vaccine demand lifted sales. The German company nevertheless remained in the red, citing ongoing investments in its oncology and infectious-disease pipeline. The quarter produced a net loss of €386.6 million, or €1.60 a share, wider than the consensus loss of €1.41. Operating loss reached €501.1 million, but was narrower than some forecasts that had anticipated a deficit of more than €700 million. Management kept its full-year guidance unchanged, forecasting 2025 revenue of €1.7 billion to €2.2 billion and total expenses of €2.6 billion to €2.8 billion. Cash, cash equivalents and investments stood at about €16 billion at the end of June, providing what the company called a “strong financial position” to fund development programs. During the quarter BioNTech advanced its oncology strategy, highlighted by investigational mRNA cancer candidate BNT327, and announced plans to acquire CureVac to expand its immunotherapy pipeline. The shares rose roughly 3 % in pre-market trading following the results.